The global fructosamine test market size is expected to grow from USD 275.9 million in 2024 to USD 399.9 million by 2034. Over the forecast period, global demand for fructosamine tests is predicted to increase at a CAGR of 3.8%.
In 2023, the global market for fructosamine tests accounted for about 1.0% of the overall global glucose monitoring market, valued at USD 26,752.5 million. However, this share is expected to improve amid rising cases of diabetes and the growing popularity of fructosamine testing.
Key Factors Boosting the Fructosamine Test Market Growth Include-
Fructosamine Test Market Overview
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | USD 266.3 million |
| Estimated Market Size (2024) | USD 275.9 million |
| Projected Fructosamine Test Market Value (2034) | USD 399.9 million |
| Value CAGR (2024 to 2034) | 3.8% |
Due to its effectiveness in monitoring immediate glucose control in diabetes, the demand for fructosamine testing is growing. It is widely used for diagnosing prediabetes and monitoring diabetes as it does not require fasting and reflects average blood sugar over a more extended period.
As an alternative to typical HbA1c testing, fructosamine provides an overview of blood glucose levels over 2-3 weeks. This is important for people who suffer from changing glucose levels or are undergoing quick treatment changes.
Fructosamine testing can be helpful during pregnancy and in conditions that impact hemoglobin. This makes it an effective instrument for accurate diabetes treatment.
There has been a spike in cases of diabetes during the last few years, and the trend is expected to further escalate in the upcoming years. According to the International Diabetes Federation, around 783 million adults will be living with diabetes in 2045. This will uplift the demand for glucose monitoring tests like fructosamine tests.
The global market for fructosamine tests experienced a CAGR of 3.3% between 2019 and 2023. Total market valuation at the end of 2023 reached USD 266.3 million. In the forecast period, the worldwide fructosamine test industry is set to expand at a CAGR of 3.8%.
| Historical CAGR (2019 to 2023) | 3.3% |
|---|---|
| Forecast CAGR (2024 to 2034) | 3.8% |
Multiple factors are expected to fuel the growth of the fructosamine test market during the assessment period. These include the rising incidence of diabetes and the growing need for quick diagnostic testing.
Diabetes, a condition marked by high blood glucose levels, carries a high risk of consequences, including renal problems, nerve damage, and heart disease. Its prevalence has sharply increased during the last few decades. For instance,
Fructosamine tests are essential in addressing the growing demand for efficient monitoring tools to treat diabetes. As the number of persons with this chronic condition keeps increasing globally, so will the demand for fructosamine tests.
Fructosamine tests are valuable tools for diabetes treatment and monitoring because they provide a dynamic, immediate evaluation of glycemic control.
Since diabetes is an ongoing condition that requires constant monitoring, being able to recognize small variations in blood glucose levels is essential for rapid treatments and modifications to treatment plans.
The hemoglobin A1c test, considered the gold standard, gives a more extended average of blood glucose levels over many months. Fructosamine tests, on the other hand, provide a more rapid evaluation of glycemic control by reflecting changes over a shorter period of time, usually two to three weeks.
The increasing awareness of the importance of routine diabetes check-ups is a primary factor driving the need for diagnostic instruments, including fructosamine testing. People and healthcare professionals are becoming more aware of the need for a proactive approach to curing diabetes as information is shared successfully.
Since fructosamine tests provide a more immediate measure of glycemic control, they are ideally suited to support the focus on early identification and treatment. Given the understanding that blood glucose levels are dynamic, patients look for convenient and effective monitoring devices.
Healthcare practitioners are also aware of the importance of fructosamine testing in providing real-time information that allows immediate changes to treatment plans. Hence, they often recommend these tests for patients with diabetic symptoms.
Increasing awareness about regular diabetes monitoring is expected to create lucrative opportunities for the fructosamine test market. Subsequently, supportive healthcare policies and government initiatives will benefit the market.
Regulatory agencies, including the Food and Drug Administration (FDA), have set strict guidelines ensuring diagnostic tests' security, effectiveness, and reliability. Because fructosamine testing involves evaluating short-term glycemic management, it is a difficult procedure requiring stringent validation.
Complying with regulatory requirements requires carrying out thorough clinical trials, demonstrating the precision and accuracy of test results, and ensuring quality assurance standards are met.
The requirement for strong clinical evidence to demonstrate the clinical utility of fructosamine tests, especially when compared to current standards such as HbA1c testing, complicated the approval process.
The approval timeline may also be affected by modifications to regulations or the addition of additional requirements due to the changing nature of the regulatory environment. Manufacturers and developers have to spend time and money on thorough documentation and compliance methods to get through this complex regulatory system.
Although these regulations protect public health, they also make it more difficult for businesses to develop novel fructosamine tests.
They may also cause a delay in the release of these essential diagnostic instruments. Hence, such stringent regulatory processes and compliance requirements could be a barrier to the growth of the fructosamine test market.
The table below gives an insight into how top nations are going to respond to the growing demand for fructosamine testing. China and India are expected to thrive rapidly due to the increasing number of diabetes patients and growing health awareness.
Market Growth Outlook by Key Countries
| Countries | Value CAGR |
|---|---|
| United States | 1.1% |
| China | 7.5% |
| Germany | 1.5% |
| United Kingdom | 1.9% |
| India | 7.9% |
The United States remains the most dominant market for fructosamine test products, holding a global market share of around 28.0% in 2023. Over the forecast period, the United States fructosamine test market is expected to register a CAGR of 1.1%. This is due to the growing adoption of fructosamine testing over traditional monitoring techniques.
Several reasons are contributing to the greater adoption of fructosamine testing in the United States. For instance, its ability to provide a more accurate overview of glycemic control than traditional approaches such as HbA1c meets the growing demand for more frequent and precise monitoring in diabetes therapy.
Secondly, the adaptability of fructosamine testing is useful in cases of quick medication changes as well as for people with fluctuating glucose levels. Thus, the growing popularity of fructosamine testing will continue to play a key role in boosting the growth of the fructosamine test industry in the United States.
The rising incidence of diabetes is another key factor expected to boost sales of fructosamine testing solutions. Similarly, innovation in fructosamine assay tests and the growing need for diabetic patient monitoring will improve the United States fructosamine test industry share.
In 2023, China's fructosamine test market size reached USD 16.7 million. Over the assessment period, demand for fructosamine tests in China is projected to grow with a robust CAGR of 7.5%. This is attributable to the rising incidence of diabetes among the exploding geriatric population.
Diabetes prevalence risks are increasing due to China's aging population. This shift in the population is expected to create a need for advanced glucose monitoring methods, particularly fructosamine testing.
Diabetes is becoming more common as the aged population grows; thus, accurate and regular monitoring is required. The combination of an increasing elderly population and the diabetes pandemic drives the uptake of novel diagnostic techniques, signaling a necessary reaction to the changing healthcare environment in China.
The below section highlights the estimated market shares of key segments, including disease indication, sample, application, and end-user. This information can be vital for companies to frame their strategies accordingly.
Market Growth Outlook by Disease Indication
| Disease Indication | Value CAGR |
|---|---|
| Diabetes I | 4.9% |
| Diabetes II | 2.4% |
| Gestational Diabetes | 7.5% |
The diabetes II segment accounted for a dominant market share of 59.4% in 2023. Over the forecast period, it is poised to advance at 2.4% CAGR. This is due to the rising prevalence of diabetes II globally, creating frequent monitoring needs.
According to the World Health Organization (WHO), more than 95% of people with diabetes have type 2 diabetes. The fructosamine test's effectiveness in assessing short-term glycemic control aligns with the chronic nature of Type II diabetes management. As a result, its demand is expected to rise with increasing cases of diabetes II.
Market Growth Outlook by Key Sample
| Sample | Value CAGR |
|---|---|
| Blood Serum | 3.5% |
| Blood Plasma | 5.9% |
The blood serum segment leads the fructosamine test market with a market value share of 81.4% in 2023. For the projection period, a CAGR of 3.5% has been predicted for the target segment. This can be attributed to the rising usage of blood samples in fructosamine testing.
Since serum doesn't include anticoagulants, it interacts with enzymatic assays less and produces consistent and accurate results. On the other hand, anticoagulants found in plasma may have an impact on the enzymatic processes used in fructosamine assays.
Serum also improves the accuracy of test results by providing a clearer background for colorimetric measurements.
In fructosamine testing, serum is highly preferred over plasma with the aim of collecting the most accurate and pure sample possible, which is essential for managing diabetes and monitoring short-term glycemic control.
Market Growth Outlook by Key Application
| Application | Value CAGR |
|---|---|
| Clinical Diagnostics for Human | 2.8% |
| Clinical Diagnostics for Animals | 5.9% |
| Research Use | 4.8% |
As per the latest analysis, clinical diagnostics for humans will remain a key application of fructosamine tests during the assessment period. In 2023, the target segment accounted for a market share of 56.4% in 2023, and it is expected to progress at 2.8% CAGR through 2034.
The main reason fructosamine testing is employed so often in human clinical diagnostics is because of its special significance in diabetes control. It provides a more immediate view of glycemic control, which is essential for modifying treatment when conditions shift swiftly.
Diabetes is a dynamic disease that requires regular monitoring, which is consistent with fructosamine’s capacity to reflect glucose levels over a period of two to three weeks. This accuracy is instrumental in clinical settings because it helps medical practitioners provide customized patient treatment.
Market Growth Outlook by Key End User
| End-user | Value CAGR |
|---|---|
| Hospitals | 2.8% |
| Ambulatory Surgical Centers | 3.9% |
| Long-Term Care Facilities | 6.2% |
| Specialty Clinics | 5.2% |
| Others | 7.6% |
The hospital segment acts as a leading end user of the fructosamine tests with a 29.8% value share in 2023. Compared to other end users, hospitals are having a higher need for fructosamine testing kits due to their large patient numbers.
Due to the high patient volume, especially for individuals with diabetes, accurate and regular monitoring of short-term glycemic control is necessary. Fructosamine testing meets the volume and urgency of hospital settings by providing quick insights into glucose levels over a few weeks.
In order to strengthen their positions, key companies are strategically making acquisitions and working on partnership agreements. Through acquisitions, businesses can grow their skills, penetrate new markets, and diversify their portfolios.
The dynamic market for fructosamine tests is promoting growth and sustainability through the ability of key players to meet consumer expectations, adjust to evolving industry trends, and maintain a competitive edge through strategic actions. Expanding into emerging regions and untapped markets can enhance a company's growth in terms of revenue.
Recent Developments in the Fructosamine Test Market
| Attribute | Details |
|---|---|
| Estimated Market Value (2024) | USD 275.9 million |
| Projected Market Size (2034) | USD 399.9 million |
| Expected Growth Rate (2024 to 2034) | 3.8% CAGR |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; South Asia & Pacific; East Asia; Western Europe; Eastern Europe; Middle East & Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, Rest of Latin America, China, Japan, South Korea, India, Association of Southeast Asian Nations, Australia & New Zealand, Rest of South Asia and Pacific, Germany, Italy, France, United Kingdom, Spain, BENELUX, Nordic Countries, Rest of Western Europe, Russia, Hungary, Poland, Rest of Eastern Europe, Saudi Arabia, Türkiye, South Africa, Other African Union, Rest of Middle East & Africa |
| Key Segments Covered | Disease Indication, Sample, Application, End-user, and Region |
| Key Companies Profiled | Beckman Coulter, Inc.; Randox Laboratories Ltd.; Fortress Diagnostics; KAMIYA BIOMEDICAL COMPANY; Abbexa; Weldon Biotech, Inc.; Eurolyser Diagnostica GmbH; F. Hoffmann-La Roche Ltd; Asahi Kasei Pharma Corporation (EKF DIAGNOSTICS); LifeSpan BioSciences, Inc; Zhejiang Kangte Biotechnology Co., Ltd.; Diazyme; Abcam plc.; Weldon Biotech, Inc.; Bio Vision; Mybiosource |
| Report Coverage | Market Forecast, Competition Intelligence, Market Dynamics and Challenges, Strategic Growth Initiatives |
Table 1: Global Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 2: Global Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 3: Global Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 4: Global Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 5: Global Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 6: Global Market Size (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
Table 7: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 8: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 9: North America Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 10: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 11: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 12: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 13: United States Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 14: United States Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 15: United States Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 16: United States Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 17: Canada Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 18: Canada Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 19: Canada Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 20: Canada Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 21: Mexico Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 22: Mexico Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 23: Mexico Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 24: Mexico Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 25: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 26: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 27: Latin America Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 28: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 29: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 30: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 31: Brazil Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 32: Brazil Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 33: Brazil Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 34: Brazil Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 35: Chile Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 36: Chile Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 37: Chile Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 38: Chile Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 39: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 40: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 41: East Asia Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 42: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 43: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 44: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 45: China Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 46: China Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 47: China Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 48: China Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 49: Japan Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 50: Japan Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 51: Japan Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 52: Japan Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 53: South Korea Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 54: South Korea Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 55: South Korea Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 56: South Korea Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 57: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 58: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 59: South Asia & Pacific Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 60: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 61: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 62: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 63: India Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 64: India Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 65: India Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 66: India Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 67: ASEAN Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 68: ASEAN Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 69: ASEAN Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 70: ASEAN Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 71: Australia & New Zealand Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 72: Australia & New Zealand Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 73: Australia & New Zealand Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 74: Australia & New Zealand Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 75: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 76: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 77: Western Europe Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 78: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 79: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 80: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 81: Germany Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 82: Germany Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 83: Germany Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 84: Germany Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 85: Italy Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 86: Italy Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 87: Italy Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 88: Italy Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 89: France Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 90: France Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 91: France Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 92: France Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 93: United Kingdom Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 94: United Kingdom Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 95: United Kingdom Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 96: United Kingdom Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 97: Spain Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 98: Spain Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 99: Spain Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 100: Spain Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 101: BENELUX Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 102: BENELUX Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 103: BENELUX Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 104: BENELUX Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 105: Nordic Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 106: Nordic Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 107: Nordic Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 108: Nordic Countries Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 109: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 110: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 111: Eastern Europe Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 112: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 113: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 114: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 115: Russia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 116: Russia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 117: Russia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 118: Russia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 119: Hungary Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 120: Hungary Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 121: Hungary Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 122: Hungary Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 123: Poland Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 124: Poland Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 125: Poland Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 126: Poland Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 127: Middle East & Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
Table 128: Middle East & Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 129: Middle East & Africa Respiratory Inhaler Devices Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 130: Middle East & Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 131: Middle East & Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 132: Middle East & Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 133: Saudi Arabia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 134: Saudi Arabia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 135: Saudi Arabia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 136: Saudi Arabia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 137: Türkiye Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 138: Türkiye Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 139: Türkiye Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 140: Türkiye Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 141: South Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 142: South Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 143: South Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 144: South Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Table 145: Other African Union Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
Table 146: Other African Union Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 147: Other African Union Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sample
Table 148: Other African Union Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-user
Figure 1: Global Market Value Share By Disease Indication 2023 (A)
Figure 2: Global Market Value Share By Sample 2023 (A)
Figure 3: Global Market Value Share By Application 2023 (A)
Figure 4: Global Market Value Share By End-user 2023 (A)
Figure 5: Global Market Value Share By Country 2023 (A)
Figure 6: Global Market Volume Analysis in (Units), 2019 to 2023
Figure 7: Global Market Volume Forecast in (Units), 2024 to 2034
Figure 8: Diabetes I Pricing Analysis (US$) for Per Unit, By Region, 2024
Figure 9: Diabetes II Pricing Analysis (US$) for Per Unit, By Region, 2024
Figure 10: Gestational Diabetes Pricing Analysis (US$) for Per Unit, By Region, 2024
Figure 11: Global Market Value Analysis (US$ million), 2019 to 2023
Figure 12: Global Market Value Forecast (US$ million), 2024 to 2034
Figure 13: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 14: Global Market Share Analysis (%), By Disease Indication, 2024 (E) to 2034 (F)
Figure 15: Global Market Y-o-Y Analysis (%), By Disease Indication, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis, By Disease Indication
Figure 17: Global Market Share Analysis (%), By Sample, 2024 (E) to 2034 (F)
Figure 18: Global Market Y-o-Y Analysis (%), By Sample, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis, By Sample
Figure 20: Global Market Share Analysis (%), By Application, 2024 (E) to 2034 (F)
Figure 21: Global Market Y-o-Y Analysis (%), By Application, 2024 to 2034
Figure 22: Global Market Attractiveness Analysis, By Application
Figure 23: Global Market Share Analysis (%), By End-user, 2024 (E) to 2034 (F)
Figure 24: Global Market Y-o-Y Analysis (%), By End-user, 2024 to 2034
Figure 25: Global Market Attractiveness Analysis, By End-user
Figure 26: Global Market Share Analysis (%), By Region, 2024 (E) to 2034 (F)
Figure 27: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 28: Global Market Attractiveness Analysis By Region, 2024 to 2034
Figure 29: North America Market Value Share By Disease Indication 2023 (A)
Figure 30: North America Market Value Share By Sample 2023 (A)
Figure 31: North America Market Value Share By Application 2023 (A)
Figure 32: North America Market Value Share By End-user 2023 (A)
Figure 33: North America Market Value Share By Country 2023 (A)
Figure 34: North America Market Value (US$ million) Analysis, 2019 to 2023
Figure 35: North America Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 37: North America Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis By Application, 2024 to 2034
Figure 39: North America Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 40: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 41: Latin America Market Value Share By Disease Indication 2023 (A)
Figure 42: Latin America Market Value Share By Sample 2023 (A)
Figure 43: Latin America Market Value Share By Application 2023 (A)
Figure 44: Latin America Market Value Share By End-user 2023 (A)
Figure 45: Latin America Market Value Share By Country 2023 (A)
Figure 46: Latin America Market Value (US$ million) Analysis, 2019 to 2023
Figure 47: Latin America Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 49: Latin America Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 50: Latin America Market Attractiveness Analysis By Application, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 52: Latin America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 53: East Asia Market Value Share By Disease Indication 2023 (A)
Figure 54: East Asia Market Value Share By Sample 2023 (A)
Figure 55: East Asia Market Value Share By Application 2023 (A)
Figure 56: East Asia Market Value Share By End-user 2023 (A)
Figure 57: East Asia Market Value Share By Country 2023 (A)
Figure 58: East Asia Market Value (US$ million) Analysis, 2019 to 2023
Figure 59: East Asia Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 60: East Asia Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 61: East Asia Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 62: East Asia Market Attractiveness Analysis By Application, 2024 to 2034
Figure 63: East Asia Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 64: East Asia Market Attractiveness Analysis By Country, 2024 to 2034
Figure 65: South Asia & Pacific Market Value Share By Disease Indication 2023 (A)
Figure 66: South Asia & Pacific Market Value Share By Sample 2023 (A)
Figure 67: South Asia & Pacific Market Value Share By Application 2023 (A)
Figure 68: South Asia & Pacific Market Value Share By End-user 2023 (A)
Figure 69: South Asia & Pacific Market Value Share By Country 2023 (A)
Figure 70: South Asia & Pacific Market Value (US$ million) Analysis, 2019 to 2023
Figure 71: South Asia & Pacific Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 72: South Asia & Pacific Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 73: South Asia & Pacific Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 74: South Asia & Pacific Market Attractiveness Analysis By Application, 2024 to 2034
Figure 75: South Asia & Pacific Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 76: South Asia & Pacific Market Attractiveness Analysis By Country, 2024 to 2034
Figure 77: Western Europe Market Value Share By Disease Indication 2023 (A)
Figure 78: Western Europe Market Value Share By Sample 2023 (A)
Figure 79: Western Europe Market Value Share By Application 2023 (A)
Figure 80: Western Europe Market Value Share By End-user 2023 (A)
Figure 81: Western Europe Market Value Share By Country 2023 (A)
Figure 82: Western Europe Market Value (US$ million) Analysis, 2019 to 2023
Figure 83: Western Europe Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 84: Western Europe Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 85: Western Europe Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 86: Western Europe Market Attractiveness Analysis By Application, 2024 to 2034
Figure 87: Western Europe Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 88: Western Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 89: Eastern Europe Market Value Share By Disease Indication 2023 (A)
Figure 90: Eastern Europe Market Value Share By Sample 2023 (A)
Figure 91: Eastern Europe Market Value Share By Application 2023 (A)
Figure 92: Eastern Europe Market Value Share By End-user 2023 (A)
Figure 93: Eastern Europe Market Value Share By Country 2023 (A)
Figure 94: Eastern Europe Market Value (US$ million) Analysis, 2019 to 2023
Figure 95: Eastern Europe Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 96: Eastern Europe Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 97: Eastern Europe Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness Analysis By Application, 2024 to 2034
Figure 99: Eastern Europe Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 100: Eastern Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 101: Middle East & Africa Market Value Share By Disease Indication 2023 (A)
Figure 102: Middle East & Africa Market Value Share By Sample 2023 (A)
Figure 103: Middle East & Africa Market Value Share By Application 2023 (A)
Figure 104: Middle East & Africa Market Value Share By End-user 2023 (A)
Figure 105: Middle East & Africa Market Value Share By Country 2023 (A)
Figure 106: Middle East & Africa Market Value (US$ million) Analysis, 2019 to 2023
Figure 107: Middle East & Africa Market Forecast & Y-o-Y growth, 2024 to 2034
Figure 108: Middle East & Africa Market Attractiveness Analysis By Disease Indication, 2024 to 2034
Figure 109: Middle East & Africa Market Attractiveness Analysis By Sample, 2024 to 2034
Figure 110: Middle East & Africa Market Attractiveness Analysis By Application, 2024 to 2034
Figure 111: Middle East & Africa Market Attractiveness Analysis By End-user, 2024 to 2034
Figure 112: Middle East & Africa Market Attractiveness Analysis By Country, 2024 to 2034
The global fructosamine test market value totaled USD 266.3 million in 2023.
The market is estimated to attain a valuation of USD 275.9 million in 2024.
The global fructosamine test market size is expected to reach USD 399.9 million by 2034.
Global demand for fructosamine tests is estimated to rise at 3.8% CAGR.
The market grew at a CAGR of 3.3% between 2019 and 2023.
The United States market reached USD 74.7 million in 2023.
Germany held around 5.9% share in the global market in 2023.
India's fructosamine test market is anticipated to progress at 7.9% CAGR through 2034.
Fructosamine test demand in China is poised to grow at 7.5% CAGR.
The hospitals segment held a prominent share of 29.8% in 2023.
The cost of fructosamine blood tests ranges from 400 to 1000 in India.
The reference range for fructosamine in non-diabetic people is about 200 to 285 umol/L is
No, it is not as good as the HbA1c test.
Explore Similar Insights
Fructosamine Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
